Skip to main content
SpringerLink
Log in

Drug Trials in Neuroprotection

  • Chapter
Optical Coherence Tomography in Multiple Sclerosis

  • 887 Accesses

Abstract

Technological development of photonic-based devices such as optical coherence tomography (OCT) has provided a new window into the multiple sclerosis (MS) brain. Acute multiple sclerosis associated optic neuritis (MSON) resembles an acute lesion model in MS leading to acute retinal neurodegeneration. Acute MSON is clinically eloquent and technically amenable to be monitored by OCT and visual function tests. Acute MSON and OCT are good partners for drug trials for neuroprotection. In this chapter, first, we describe the ongoing randomized clinical trials (RCTs) in acute MSON and MS using OCT. Second, we explain the strengths of this clinical-technological paradigm. Third, we discuss challenges and provide solutions to overcome some clinico-epidemiological, technical, and biological limitations. Finally, we propose a design for an RCT evaluating neuroprotective drugs in placebo-controlled trials of acute neuroprotection in acute MSON by using OCT and low-contrast vision as outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.

    Article  CAS  PubMed  Google Scholar 

  2. Tallantyre EC, Bo L, Al-Rawashdeh O, Owens T, Polman CH, Lowe JS, et al. Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England). 2010;16(4):406–11.

    Article  Google Scholar 

  3. Fazekas F, Soelberg-Sorensen P, Comi G, Filippi M. MRI to monitor treatment efficacy in multiple sclerosis. J Neuroimaging. 2007;17 Suppl 1:50S–5.

    Article  PubMed  Google Scholar 

  4. Yang EB, Hood DC, Rodarte C, Zhang X, Odel JG, Behrens MM. Improvement in conduction velocity after optic neuritis measured with the multifocal VEP. Invest Ophthalmol Vis Sci. 2007;48(2):692–8.

    Article  PubMed  Google Scholar 

  5. Cadavid D BL, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch L, et al., for the RENEW Study Investigators, editor. Efficacy analysis of the anti-lingo-1 monoclonal antibody biib033 in acute optic neuritis: the renew trial (p7.202). Poster session vii: MS and CNS inflammatory diseases: clinical trials. Washington, DC: American Academy of Neurology; 2015.

    Google Scholar 

  6. De Stefano N, Airas L, Grigoriadis N, Mattle HP, O'Riordan J, Oreja-Guevara C, et al. Clinical relevance of brain volume measures in multiple sclerosis. CNS Drugs. 2014;28(2):147–56.

    Article  PubMed  Google Scholar 

  7. Jacobsen C, Hagemeier J, Myhr KM, Nyland H, Lode K, Bergsland N, et al. Brain atrophy and disability progression in multiple sclerosis patients: a 10-year follow-up study. J Neurol Neurosurg Psychiatry. 2014;85(10):1109–15.

    Article  PubMed  Google Scholar 

  8. Summers M, Fisniku L, Anderson V, Miller D, Cipolotti L, Ron M. Cognitive impairment in relapsing-remitting multiple sclerosis can be predicted by imaging performed several years earlier. Mult Scler (Houndmills, Basingstoke, England). 2008;14(2):197–204.

    Article  Google Scholar 

  9. Parisi V, Manni G, Spadaro M, Colacino G, Restuccia R, Marchi S, et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci. 1999;40(11):2520–7.

    CAS  PubMed  Google Scholar 

  10. Petzold A, de Boer JF, Schippling S, Vermersch P, Kardon R, Green A, et al. Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2010;9(9):921–32.

    Article  PubMed  Google Scholar 

  11. Syc SB, Saidha S, Newsome SD, Ratchford JN, Levy M, Ford E, et al. Optical coherence tomography segmentation reveals ganglion cell layer pathology after optic neuritis. Brain. 2012;135(Pt 2):521–33.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Saidha S, Syc SB, Ibrahim MA, Eckstein C, Warner CV, Farrell SK, et al. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain. 2011;134(Pt 2):518–33.

    Article  PubMed  Google Scholar 

  13. Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol. 2006;59(6):963–9.

    Article  PubMed  Google Scholar 

  14. Noval S, Contreras I, Rebolleda G, Munoz-Negrete FJ. Optical coherence tomography versus automated perimetry for follow-up of optic neuritis. Acta Ophthalmol Scand. 2006;84(6):790–4.

    Article  PubMed  Google Scholar 

  15. Costello F, Hodge W, Pan YI, Eggenberger E, Coupland S, Kardon RH. Tracking retinal nerve fiber layer loss after optic neuritis: a prospective study using optical coherence tomography. Mul Scler (Houndmills, Basingstoke, England). 2008;14(7):893–905.

    Article  CAS  Google Scholar 

  16. Henderson AP, Altmann DR, Trip AS, Kallis C, Jones SJ, Schlottmann PG, et al. A serial study of retinal changes following optic neuritis with sample size estimates for acute neuroprotection trials. Brain. 2010;133(9):2592–602.

    Article  PubMed  Google Scholar 

  17. Kupersmith MJ, Anderson S, Kardon R. Predictive value of 1 month retinal nerve fiber layer thinning for deficits at 6 months after acute optic neuritis. Mult Scler (Houndmills, Basingstoke, England). 2013;19(13):1743–8.

    Article  Google Scholar 

  18. Costello F, Hodge W, Pan YI, Eggenberger E, Freedman MS. Using retinal architecture to help characterize multiple sclerosis patients. Can J Ophthalmol. 2010;45(5):520–6.

    Article  PubMed  Google Scholar 

  19. Green AJ, McQuaid S, Hauser SL, Allen IV, Lyness R. Ocular pathology in multiple sclerosis: retinal atrophy and inflammation irrespective of disease duration. Brain. 2010;133(Pt 6):1591–601.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Saidha S, Syc SB, Durbin MK, Eckstein C, Oakley JD, Meyer SA, et al. Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness. Mult Scler (Houndmills, Basingstoke, England). 2011;17(12):1449–63.

    Article  Google Scholar 

  21. Walter SD, Ishikawa H, Galetta KM, Sakai RE, Feller DJ, Henderson SB, et al. Ganglion cell loss in relation to visual disability in multiple sclerosis. Ophthalmology. 2012;119(6):1250–7.

    Article  PubMed Central  PubMed  Google Scholar 

  22. Forooghian F, Sproule M, Westall C, Gordon L, Jirawuthiworavong G, Shimazaki K, et al. Electroretinographic abnormalities in multiple sclerosis: Possible role for retinal autoantibodies. Doc Ophthalmol. 2006;113(2):123–32.

    Article  PubMed  Google Scholar 

  23. Heide AC, Kraft GH, Slimp JC, Gardner JC, Posse S, Serafini S, et al. Cerebral n-acetylaspartate is low in patients with multiple sclerosis and abnormal visual evoked potentials. AJNR Am J Neuroradiol. 1998;19(6):1047–54.

    CAS  PubMed  Google Scholar 

  24. Rocca MA, Mesaros S, Preziosa P, Pagani E, Stosic-Opincal T, Dujmovic-Basuroski I, et al. Wallerian and trans-synaptic degeneration contribute to optic radiation damage in multiple sclerosis: A diffusion tensor MRI study. Mult Scler (Houndmills, Basingstoke, England). 2013;19(12):1610–7.

    Article  Google Scholar 

  25. Gabilondo I, Martinez-Lapiscina EH, Martinez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, et al. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol. 2014;75(1):98–107.

    Google Scholar 

  26. Balk LJ, Steenwijk MD, Tewarie P, Daams M, Killestein J, Wattjes MP, et al. Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2014;27.

    Google Scholar 

  27. Sepulcre J, Murie-Fernandez M, Salinas-Alaman A, Garcia-Layana A, Bejarano B, Villoslada P. Diagnostic accuracy of retinal abnormalities in predicting disease activity in ms. Neurology. 2007;68(18):1488–94.

    Article  PubMed  Google Scholar 

  28. Toledo J, Sepulcre J, Salinas-Alaman A, Garcia-Layana A, Murie-Fernandez M, Bejarano B, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England). 2008;14(7):906–12.

    Article  CAS  Google Scholar 

  29. Talman LS, Bisker ER, Sackel DJ, Long Jr DA, Galetta KM, Ratchford JN, et al. Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis. Ann Neurol. 2010;67(6):749–60.

    PubMed Central  PubMed  Google Scholar 

  30. Grazioli E, Zivadinov R, Weinstock-Guttman B, Lincoff N, Baier M, Wong JR, et al. Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci. 2008;268(1–2):12–7.

    Article  PubMed  Google Scholar 

  31. Siger M, Dziegielewski K, Jasek L, Bieniek M, Nicpan A, Nawrocki J, et al. Optical coherence tomography in multiple sclerosis: thickness of the retinal nerve fiber layer as a potential measure of axonal loss and brain atrophy. J Neurol. 2008;255(10):1555–60.

    Article  PubMed  Google Scholar 

  32. Saidha S, Sotirchos ES, Oh J, Syc SB, Seigo MA, Shiee N, et al. Relationships between retinal axonal and neuronal measures and global central nervous system pathology in multiple sclerosis. JAMA Neurol. 2013;70(1):34–43.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Garcia-Martin E, Polo V, Larrosa JM, Marques ML, Herrero R, Martin J, et al. Retinal layer segmentation in patients with multiple sclerosis using spectral domain optical coherence tomography. Ophthalmology. 2014;121(2):573–9.

    Article  PubMed  Google Scholar 

  34. Suhs KW, Hein K, Sattler MB, Gorlitz A, Ciupka C, Scholz K, et al. A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis. Ann Neurol. 2012;72(2):199–210.

    Article  PubMed  Google Scholar 

  35. Serbecic N, Aboul-Enein F, Beutelspacher SC, Vass C, Kristoferitsch W, Lassmann H, et al. High resolution spectral domain optical coherence tomography (SD-OCT) in multiple sclerosis: the first follow up study over two years. PLoS One. 2011;6(5), e19843.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  36. Kapoor R RR, Hickman S, Toosy A, Sharrack B, Mallik S, et al. Phenytoin is neuroprotective in acute optic neuritis: results of a phase 2 randomized controlled trial. Washington, DC: American Academy of Neurology; 2015.

    Google Scholar 

  37. Martínez-Lapiscina EH, Fraga-Pumar E, Ortiz-Perez S, Torres-Torres R, Andorra M, Llufriu S, Zubizarreta I, Saiz A, Sanchez-Dalmau B, Villoslada P. Dynamics of retinal injury after acute optic neuritis. Ann Neurol. 2015;77(3):517–28.

    Article  PubMed  Google Scholar 

  38. Kupersmith MJ, Gal RL, Beck RW, Xing D, Miller N. Visual function at baseline and 1 month in acute optic neuritis: predictors of visual outcome. Neurology. 2007;69(6):508–14.

    Article  CAS  PubMed  Google Scholar 

  39. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. Am J Ophthalmol. 1996;121(5):547–53.

    Article  CAS  PubMed  Google Scholar 

  40. Martínez-Lapiscina EH, Gabilondo I, Fraga-Pumar E, Ortiz-Perez S, Torres-Torres R, Andorrà M, et al. Retrograde axonal and neuronal degeneration of the retina in acute optic neuritis. Mult Scler (Houndmills, Basingstoke, England). 2014;20:357.

    Google Scholar 

  41. Mowry EM, Loguidice MJ, Daniels AB, Jacobs DA, Markowitz CE, Galetta SL, et al. Vision related quality of life in multiple sclerosis: correlation with new measures of low and high contrast letter acuity. J Neurol Neurosurg Psychiatry. 2009;80(7):767–72.

    Article  CAS  PubMed  Google Scholar 

  42. Schinzel J, Zimmermann H, Paul F, Ruprecht K, Hahn K, Brandt AU, et al. Relations of low contrast visual acuity, quality of life and multiple sclerosis functional composite: a cross-sectional analysis. BMC Neurol. 2014;14(1):31.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, et al. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007;68(16):1299–304.

    Article  CAS  PubMed  Google Scholar 

  44. Graves J, Galetta SL, Palmer J, Margolin DH, Rizzo M, Bilbruck J, et al. Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis. Mult Scler (Houndmills, Basingstoke, England). 2013;19(10):1302–9.

    Article  CAS  Google Scholar 

  45. Martinez-Lapiscina EH, Fraga-Pumar E, Pastor X, Gomez M, Conesa A, Lozano-Rubi R, et al. Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain), 2008–2012. J Neurol. 2014;261(4):759–67.

    Article  CAS  PubMed  Google Scholar 

  46. Kupersmith MJ, Mandel G, Anderson S, Meltzer DE, Kardon R. Baseline, one and three month changes in the peripapillary retinal nerve fiber layer in acute optic neuritis: relation to baseline vision and MRI. J Neurol Sci. 2011;308(1–2):117–23.

    Article  PubMed  Google Scholar 

  47. Cadavid D, Ziemssen F, Butzkueven H, Balcer LJ, Galetta SL, Rahilly A, et al. A phase ii study of the anti-lingo-1 monoclonal antibody, biib033, in subjects with acute optic neuritis: baseline data. Mult Scler (Houndmills, Basingstoke, England). 2014;20(1 suppl):387–8.

    Google Scholar 

  48. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Systematic Reviews. 2012;4:CD001430.

    Google Scholar 

  49. Lienert C, Schawalder G, Findling O, Kamm CP, Humpert S, Mugglin A, et al. Tolerance of intravenous methylprednisolone for relapse treatment in demyelinating CNS disease. Swiss Med Wkly. 2013;143, w13783.

    PubMed  Google Scholar 

  50. Hoffman S, Podgurski A. The use and misuse of biomedical data: is bigger really better? Am J Law Med. 2013;39(4):497–538.

    PubMed  Google Scholar 

  51. Pierro L, Gagliardi M, Iuliano L, Ambrosi A, Bandello F. Retinal nerve fiber layer thickness reproducibility using seven different OCT instruments. Invest Ophthalmol Vis Sci. 2012;53(9):5912–20.

    Article  PubMed  Google Scholar 

  52. Saidha S, Sotirchos ES, Ibrahim MA, Crainiceanu CM, Gelfand JM, Sepah YJ, et al. Microcystic macular oedema, thickness of the inner nuclear layer of the retina, and disease characteristics in multiple sclerosis: a retrospective study. Lancet Neurol. 2012;11(11):963–72.

    Article  PubMed Central  PubMed  Google Scholar 

  53. Burggraaff MC, Trieu J, de Vries-Knoppert WA, Balk L, Petzold A. The clinical spectrum of microcystic macular edema. Invest Ophthalmol Vis Sci. 2014;55(2):952–61.

    Article  PubMed  Google Scholar 

  54. Cleary PA, Beck RW, Anderson Jr MM, Kenny DJ, Backlund JY, Gilbert PR. Design, methods, and conduct of the optic neuritis treatment trial. Control Clin Trials. 1993;14(2):123–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center of Neuroimmunology and Neurology Department, Institute of Biomedical Research August Pi Sunyer (IDIBAPS) – Hospital Clinic of Barcelona, Barcelona, Spain

    Elena H. Martínez-Lapiscina MD, PhD, Bernardo Sanchez-Dalmau MD & Pablo Villoslada MD, PhD

Authors
  1. Elena H. Martínez-Lapiscina MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernardo Sanchez-Dalmau MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Pablo Villoslada MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elena H. Martínez-Lapiscina MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Neuroimmunology, VU Medical Center, Expertise Center Neuro-ophthalmology, Departments of Neurology and Ophthalmology, Amsterdam, The Netherlands, Moorfields Eye Hospital, Department of Neuro-Ophthalmology, London, UK, UCL Institute of Neurology, London, United Kingdom

    Axel Petzold

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Martínez-Lapiscina, E.H., Sanchez-Dalmau, B., Villoslada, P. (2016). Drug Trials in Neuroprotection. In: Petzold, A. (eds) Optical Coherence Tomography in Multiple Sclerosis. Springer, Cham. https://doi.org/10.1007/978-3-319-20970-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20970-8_12

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-20969-2

  • Online ISBN: 978-3-319-20970-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation